{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:14:05Z","timestamp":1789874045508,"version":"4.0.1"},"reference-count":177,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T00:00:00Z","timestamp":1411948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.wileyhealthlearning.com\/acs.aspx\">Answer questions and earn CME\/CNE<\/jats:ext-link>\n                  <\/jats:p>\n                  <jats:p>\n                    Multiple myeloma (MM) is a cancer of antibody\u2010producing plasma cells. The pathognomonic laboratory finding is a monoclonal immunoglobulin or free light chain in the serum and\/or urine in association with bone marrow infiltration by malignant plasma cells. MM develops from a premalignant condition, monoclonal gammopathy of undetermined significance (MGUS), often via an intermediate stage termed smoldering multiple myeloma (SMM), which differs from active myeloma by the absence of disease\u2010related end\u2010organ damage. Unlike MGUS and SMM, active MM requires therapy. Over the past 6 decades, major advancements in the care of MM patients have occurred, in particular, the introduction of novel agents (ie, proteasome inhibitors, immunomodulatory agents) and the implementation of hematopoietic stem cell transplantation in suitable candidates. The effectiveness and good tolerability of novel agents allowed for their combined use in induction, consolidation, and maintenance therapy, resulting in deeper and more sustained clinical response and extended progression\u2010free and overall survival. Previously a rapidly lethal cancer with few therapeutic options, MM is the hematologic cancer with the most novel US Food and Drug Administration\u2010approved drugs in the past 15 years. These advances have resulted in more frequent long\u2010term remissions, transforming MM into a chronic illness for many patients.\n                    <jats:bold>CA Cancer J Clin 2014;64:422\u2013444. \u00a9 2014 American Cancer Society.<\/jats:bold>\n                  <\/jats:p>","DOI":"10.3322\/caac.21252","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T16:46:17Z","timestamp":1412009177000},"page":"422-444","source":"Crossref","is-referenced-by-count":88,"title":["Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back"],"prefix":"10.3322","volume":"64","author":[{"given":"Giada","family":"Bianchi","sequence":"first","affiliation":[{"name":"Hematology Oncology Fellow, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology Dana Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Professor of Medicine, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology Dana Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"e_1_2_10_3_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. SEER Cancer Statistics Factsheets: Myeloma. Bethesda MD: National Cancer Institute; 2014."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-387324"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-331454"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130249"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb06059.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.1.219"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.13931"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194241"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195008"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.60"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1038"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108357"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.296"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.237"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1106428"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90586-2"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.814637"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.02.015"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07064"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09837"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.199"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","unstructured":"DarwinC. On the Origin of Species by Means of Natural Selection or the Preservation of Favoured Races in the Struggle for Life. London UK: John Murray; 1859.","DOI":"10.5962\/bhl.title.68064"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1853"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0095"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(73)90127-7"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPENJ68FFBRIYB"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1248705"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-008-0607-4"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.11.006"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361386"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V114.22.614.614","article-title":"Multicenter, randomized, open\u2010label, phase III trial of lenalidomide\u2010dexamethasone (Len\/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis","volume":"114","author":"Mateos MV","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2037"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-118"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.489"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432203"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10759"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.8791"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00365.x"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0329"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.61"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8919"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7506"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1411"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.3945"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379164"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.12.557"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-544759"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.04.027"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21191"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6081"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-297325"},{"key":"e_1_2_10_63_1","unstructured":"University Hospital Toulous. Dana\u2010Farber Cancer Institute Celgene Corporation Janssen\u2010Cilag Ltd. Study comparing conventional dose combination RVD to high\u2010dose treatment with ASCT in the initial myeloma up to 65 years (IFM\/DFCI2009). NCT01191060.clinicaltrials.gov\/show\/NCT01191060. Accessed September 11 2014."},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-204651"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3463"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1610"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_10_78_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood.V116.21.310.310","article-title":"Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005\u201002","volume":"116","author":"Attal M","year":"2010","journal-title":"Blood"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.7900"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01533.x"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.731"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.0086"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2119"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074534"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23390"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.07.007"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920109787847493"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412110"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(10)70004-7"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.190"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-452375"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00120-5"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7725095"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.06.035"},{"key":"e_1_2_10_102_1","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima T","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07573.x"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.3087"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-459883"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.152"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-172734"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2008.08.002"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2543"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-374249"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373514"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-357038"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145235"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.335"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.07.007"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701975"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.934"},{"key":"e_1_2_10_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.173"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1209038"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2010.11.004"},{"key":"e_1_2_10_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2731"},{"key":"e_1_2_10_127_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.443"},{"key":"e_1_2_10_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.08.007"},{"key":"e_1_2_10_129_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-500033"},{"key":"e_1_2_10_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00939-5"},{"key":"e_1_2_10_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387365"},{"key":"e_1_2_10_132_1","article-title":"ACY\u20101215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and dexamethasone (dex), is well tolerated without dose limiting toxicity (DLT) in patients (Pts) with multiple myeloma (MM) at doses demonstrating biologic activity: interim results of a phase 1b trial [abstract]","volume":"122","author":"Yee A","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_10_133_1","article-title":"ACY\u20101215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM) [abstract]","volume":"122","author":"Raje N","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_10_134_1","doi-asserted-by":"publisher","DOI":"10.1038\/415092a"},{"key":"e_1_2_10_135_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263236"},{"key":"e_1_2_10_136_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303099"},{"key":"e_1_2_10_137_1","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.V116.21.4074.4074","article-title":"Targeting IRE1 alpha\u2010XBP1 pathway is a novel therapeutic strategy in multiple myeloma","volume":"116","author":"Mimura N","year":"2010","journal-title":"Blood"},{"key":"e_1_2_10_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10317"},{"key":"e_1_2_10_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70169-4"},{"key":"e_1_2_10_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.111"},{"key":"e_1_2_10_141_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3112"},{"key":"e_1_2_10_142_1","doi-asserted-by":"publisher","DOI":"10.2217\/14796694.3.6.639"},{"key":"e_1_2_10_143_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3434"},{"key":"e_1_2_10_144_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9788"},{"key":"e_1_2_10_145_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5725"},{"key":"e_1_2_10_146_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007258"},{"key":"e_1_2_10_147_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"e_1_2_10_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70398-X"},{"key":"e_1_2_10_149_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.1"},{"key":"e_1_2_10_150_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481325"},{"key":"e_1_2_10_151_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.7068"},{"issue":"5","key":"e_1_2_10_152_1","article-title":"Panorama 1: a randomized, double\u2010blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma [abstract]","volume":"32","author":"Richardson PG","year":"2014","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396853"},{"key":"e_1_2_10_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.017"},{"key":"e_1_2_10_155_1","first-page":"539","article-title":"The biological sequelae of stromal cell\u2010derived factor\u20101alpha in multiple myeloma","volume":"1","author":"Hideshima T","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_10_156_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186668"},{"key":"e_1_2_10_157_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269126"},{"key":"e_1_2_10_158_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-191577"},{"key":"e_1_2_10_159_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2649"},{"key":"e_1_2_10_160_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_2_10_161_1","article-title":"Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma [abstract]","volume":"122","author":"Plesner T","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_10_162_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.118"},{"key":"e_1_2_10_163_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri823"},{"key":"e_1_2_10_164_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_2_10_165_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-277137"},{"key":"e_1_2_10_166_1","article-title":"Blockade of PD\u20101 in combination with dendritic cell\/myeloma fusion cell vaccination following autologous stem cell transplantation [abstract]","volume":"120","author":"Rosenblatt J","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"issue":"15","key":"e_1_2_10_167_1","article-title":"A phase 1 (Ph1) trial of MK\u20103475 combined with lenalidomide (Len) and low\u2010dose dexamethasone (Dex) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"32","author":"DiCapua Siegel DS","year":"2014","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_168_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"e_1_2_10_169_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12861"},{"key":"e_1_2_10_170_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24758"},{"key":"e_1_2_10_171_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806285"},{"key":"e_1_2_10_172_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62051-X"},{"key":"e_1_2_10_173_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"e_1_2_10_174_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200507073530120"},{"key":"e_1_2_10_175_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"e_1_2_10_176_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"e_1_2_10_177_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_10_178_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9641"}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.21252","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:24:18Z","timestamp":1762363458000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,29]]},"references-count":177,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.3322\/caac.21252"],"URL":"https:\/\/doi.org\/10.3322\/caac.21252","archive":["Portico"],"relation":{},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"value":"0007-9235","type":"print"},{"value":"1542-4863","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,29]]}}}